Reflections on a career in Pharmaceutical Statistical Sciences: My Journey. James R. Johnson, PhD (UD04)

Size: px
Start display at page:

Download "Reflections on a career in Pharmaceutical Statistical Sciences: My Journey. James R. Johnson, PhD (UD04)"

Transcription

1 Reflections on a career in Pharmaceutical Statistical Sciences: My Journey James R. Johnson, PhD (UD04) 1

2 My Journey 7 Different Pharmaceutical Companies 30 years (1983 to 2013) Retired to Consulting and Teaching 7 different Therapeutic Areas Cardiology / Pulmonary Medicine Nuclear medicine / Imaging Dermatology Infectious Diseases Oncology Anesthesia Neurology Worldwide: US, Germany, UK, India, Australia 2

3 My Education BS, MS, PhD I always wanted to be a Marine Biologist or Veterinarian.. and ended up a Pharmaceutical Statistician. With No Regrets! 3

4 Question Can you tell me when and where the first recorded clinical trial was published? 4

5 Brief History of Clinical Trials First Recorded Clinical Trial: BC Book of Daniel 1:1-17 tell the story, Versus describe the experiment The Lion of King Nebuchadnezzar II at the Gates of Babylon 5

6 Daniel 1:1-17 (The Hypothesis) (12) Prove thy servants, I beseech thee, ten days; and let them give us pulse to eat, and water to drink. (13) Then let our countenances be looked upon before thee, and the countenance of the children that eat of the portion of the king's meat: and as thou seeth, deal with thy servants. The Lion of King Nebuchadnezzar II at the Gates of Babylon 6

7 Daniel 1:1-17 (Observation) (14) So he consented to them in this matter, and proved them ten days. (15) And at the end of ten days their countenances appeared fairer and fatter in flesh than all the children which did eat the portion of the king's meat. The Lion of King Nebuchadnezzar II at the Gates of Babylon 7

8 Daniel 1:1-17 (Results) (16) Thus Melzar took away the portion of their meat, and the wine that they should drink; and gave them pulse. (17) As for these four children, God gave them knowledge and skill in all learning and wisdom: and Daniel had understanding in all visions and dreams. The Lion of King Nebuchadnezzar II at the Gates of Babylon 8

9 Drugs By Design What makes a good Drug (or compound)? Highly Selective for Disease Target High Potency, Uniform Dose Low Toxicity Patient Friendly Dosage Form Route of Administration Frequency of Dosage Reliable, Reproducible, Stable Manufacturing Drug Substance Drug Product Container Delivery Systems 9

10 Stages of Drug Development Formulation à Pilot Plant à Stability Testing à Manufacturing Phase I Target ID Disease Biology Chemistry Medicinal Chemistry Assay Dev. HTS Pharmacology Pre- Clinical Dev. Animal Tox ADME Rx Delivery Safety PK PD (~200) Phase II Dose Finding Initial Efficacy Safety (~300) Phase III Efficacy Safety Trials Large Pop. (~1000) FDA Review EMEA Review Indefinite ~3 yrs ~3 yrs ~1 yr ~2 yrs ~3 yrs ~1.5 yrs Approximate Time (Years) 10

11 Stages of Drug Development Costs Probability Probability of Success Total Cumulative Costs 1/10,000 Target ID Medicinal Chemistry Pre- Clinical Dev Phase I Phase II Phase III Regulatory Review Indefinite ~3 yrs ~3 yrs ~1 yr ~2 yrs ~3 yrs ~1.5 yrs Approximate Time (Years) 11

12 Rational Drug Development Plan Marketing Clinical Development CMC Toxicology Label, Target Product Profile Clinical Development Plan Legal Regulatory Preclinical Development Drug Safety 12

13 Randomized Clinical Trials History has lead us to one of the single most important aspects of the history of clinical research: Randomized Controlled Clinical Trials RCT s are the Gold Standard for testing new intervention(s) in a population 13

14 A Way of Thinking Category Traditional View Statistical View Reproducibility of Events View of Experimental Units Precision in Determinations from data Granularity in Examining Data Certainty and Determinism Individuals Certain Knowledge Examine ALL data Randomness and Shochasticism Distributions and Populations Estimation, Variability, and Bias Data reduction 14

15 A Way of Thinking Statistician vs. Clinician: A Clinician treats one patient at a time using an established protocol. A Statistician helps the Clinician treat 1000 s of patients by helping them develop the protocol to treat a single patient. 15

16 Study Design, Methods, Analysis 1. Study Design Ø Sets the ground work for the study. We begin with the end in mind. 2. Study Methods Ø Implementing the Plan outlined in the Study Design. 3. Study Analysis Ø Rational and focused analysis of the planned study design, implemented with solid methodology generally results in observations that are true to the experiment. 4. Feedback Loop Ø The Study Analysis serves to provide a check on the Original Study Design. Is an indicator of how well the design worked in validating the experiment 1 STUDY DESIGN 4 2 STUDY METHODS 3 STUDY ANALYSIS

17 My NDA s: Funny Stories Ceftin (Ceferoxine axetil) Antibiotic Treatment of: Ear Infections Gonorrhea ß How is this related to ear infections? Sinus Infections Fluticasone Ointment Dermatological Treatment of: Skin Rash ß Was that rash really on that part! 17

18 Early on. I could find almost any association if I looked hard enough 18

19 Then I went to replicated Studies.Multiple Trials? 19

20 Where is the profession going.evolve to Bayesian! 20

21 Pharmaceutical Statistician Statistical Programmer Highly rewarding! Never a dull moment! Meet and work with the smartest and nicest people. Always Learning. I would do it again. 21

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT

MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT MAXIMIZING THE VALUE OF CLINICAL TRIALS DATA: A COLLABORATIVE FRAMEWORK FOR DATA STANDARDS GOVERNANCE FROM DATA DEFINITION TO KNOWLEDGE MANAGEMENT PharmaSUG Single Day Event Using Standards, Even for Non-Standard

More information

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA

More information

A Life-cycle Approach to Dose Finding Studies

A Life-cycle Approach to Dose Finding Studies A Life-cycle Approach to Dose Finding Studies Rajeshwari Sridhara, Ph.D. Director, Division of Biometrics V Center for Drug Evaluation and Research, USFDA This presentation reflects the views of the author

More information

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

Regulatory Issues and Drug Product Approval for Biopharmaceuticals Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop

More information

Introduction to Drug Design and Discovery

Introduction to Drug Design and Discovery Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,

More information

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development

Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality

More information

From Bench to Bedside. Russ H. Read June 23, 2014

From Bench to Bedside. Russ H. Read June 23, 2014 From Bench to Bedside Russ H. Read June 23, 2014 Talent Required Scientists, clinicians, technicians, chemists, biologists, pharmacologists, toxicologists, research associates, regulatory experts, manufacturing

More information

Competing & Collaborating to Achieve Successful Drug Repositioning

Competing & Collaborating to Achieve Successful Drug Repositioning Competing & Collaborating to Achieve Successful Drug Repositioning Noel Southall, Ph.D. National Human Genome Research Institute National Institutes of Health July 14, 2011 NIH Chemical Genomics Center

More information

BIOSTATISTICAL METHODS

BIOSTATISTICAL METHODS BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS Steps to New Drug Discovery Get idea for drug target Develop a bioassay Screen chemical compounds

More information

EMEA/CHMP WORKSHOP Draft guideline on requirements for first-in. in- man clinical trials for potential high-risk medicinal products

EMEA/CHMP WORKSHOP Draft guideline on requirements for first-in. in- man clinical trials for potential high-risk medicinal products EMEA/CHMP WORKSHOP Draft guideline on requirements for first-in in- man clinical trials for potential high-risk medicinal products THE EFPIA POSITION EMEA Workshop London 12 th June 2007 1 SOME BACKGROUND

More information

Exploratory clinical trials workshop

Exploratory clinical trials workshop Exploratory clinical trials workshop Yves Donazzolo, Grenoble / Lyon Dominique Tremblay, Paris AGAH / Club Phase I meeting Lyon, April 28 & 29, 2009 Topics Introduction Definitions Nonclinical safety studies

More information

Date/Lecturer Class Topic Readings 01/28/10 Brookman

Date/Lecturer Class Topic Readings 01/28/10 Brookman Course Director: Sheldon, Ph.D. 01/28/10 1 I. Course Description and Requirements II. Historical Perspectives and Overview of Drug Development a. Evolution of the pharmaceutical industry b. Changing development

More information

HESI ILSI Health and Environmental Sciences Institute

HESI ILSI Health and Environmental Sciences Institute HESI ILSI Health and Environmental Sciences Institute WORKSHOP ON THE VALUE OF JUVENILE ANIMAL STUDIES WASHINGTON DC 5/6 MAY 2010 A Pediatric Clinical PerspectiveClinical Perspective Klaus Rose, Granzer

More information

Introduction to clinical trials Magnus Kjaer

Introduction to clinical trials Magnus Kjaer Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions

More information

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH

BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH BIOSTATISTICAL METHODS FOR TRANSLATIONAL & CLINICAL RESEARCH Phase 0 Trials: EARLY-PHASE CLINICAL TRIALS CLINICAL PHASE Clinical Studies: Class of all scientific approaches to evaluate Disease Prevention,

More information

Antibody Discovery at Evotec

Antibody Discovery at Evotec Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic

More information

CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS

CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS Guideline Title Clinical Requirements for Locally Applied, Locally Acting Products, Containing Known Constituents

More information

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner

The Role of a Clinical Statistician in Drug Development By: Jackie Reisner The Role of a Clinical Statistician in Drug Development By: Jackie Reisner Types of studies within clinical development Phase I Phase II Phase III Phase IV Phase I First Human Dose (FHD) Young healthy

More information

Role of Academic Investigators in Drug Development

Role of Academic Investigators in Drug Development DTRCS Regulatory Education Seminar, June 12, 2007 Role of Academic Investigators in Drug Development Howard Lee, MD, PhD Associate Adjunct Professor Director, Center for Drug Terminology Sponsor Investigator

More information

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,

More information

Introduction to clinical trials

Introduction to clinical trials Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words

More information

Acceptance of Foreign Clinical Data A U.S. Perspective

Acceptance of Foreign Clinical Data A U.S. Perspective Acceptance of Foreign Clinical Data A U.S. Perspective Robert L. Justice, M.D., M.S. 9 th Kitasato University Harvard School of Public Health Symposium Disclaimer The views expressed in this presentation

More information

Speakers Title & Biography

Speakers Title & Biography Speakers Title & Biography Dr. Janice M. Soreth Deputy Director, FDA Europe Office/CDER, Liaison to EMA Dr. Soreth 20-year agency veteran with unparalleled experience, including serving as CDER's director

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

International Transfers of Personal Data at sanofi-aventis R & D

International Transfers of Personal Data at sanofi-aventis R & D International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF

More information

Drug-Device Combination Product Development: INDs for Device Companies

Drug-Device Combination Product Development: INDs for Device Companies Drug-Device Combination Product Development: INDs for Device Companies David Armbruster Global Program Manager April 24, 2013 Drug-Device Combination Product Development -or- The scenic route to an IND

More information

Anti-cancer drug discovery: from bench to bedside

Anti-cancer drug discovery: from bench to bedside Anti-cancer drug discovery: from bench to bedside Christian BAILLY, Ph.D. christian.bailly@pierre-fabre.com Pierre Fabre CDMO October 2nd, 2015 1 Christian BAILLY - Montpellier, October 2 nd, 2015 MOLECULES

More information

Introduction to Experimental Medicine

Introduction to Experimental Medicine Introduction to Experimental Medicine Peter P Doran Experimental Medicine Studies that provide information on health and disease Major goal is to identify How we stay well? Why we get sick? How we can

More information

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

Development of a new medicinal product. as. MUDr. Martin Votava, PhD. Development of a new medicinal product as. MUDr. Martin Votava, PhD. Development and registration of a medicinal product Costs of development: 800 mil USD Time to develop: 10 years Successfulness: 0,005%

More information

Structure and Mandate of FDA

Structure and Mandate of FDA Structure and Mandate of FDA Leonard Sacks, M.D. Office of Medical Policy Center for Drug Evaluation and Research FDA FDA Clinical Investigator Training Course November 13, 2018 Mission of regulatory agencies

More information

The Drug Development Process and Design of Clinical Trials

The Drug Development Process and Design of Clinical Trials The Drug Development Process and Design of Clinical Trials Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 Clinical Trial Design Guidance Clinical Trial:

More information

5/23/2016. The Drug Development Process and Design of Clinical Trials. Clinical Trial Design Guidance. Regulatory Definitions

5/23/2016. The Drug Development Process and Design of Clinical Trials. Clinical Trial Design Guidance. Regulatory Definitions The Drug Development Process and Design of Clinical Trials Darlene Kitterman, MBA Director, Investigator Support & Integration Services May 25, 2016 Clinical Trial Design Guidance Clinical Trial: a prospective

More information

Oral vaccines to protect patients against Clostridium difficile infection

Oral vaccines to protect patients against Clostridium difficile infection Oral vaccines to protect patients against Clostridium difficile infection Jonathan Kearsey: Leads To Development Antibiotics and their alternatives-fixing and feeding the pipeline Project number: 601810

More information

Drug Development - Points to Consider

Drug Development - Points to Consider Drug Development - Points to Consider The Regulator View ד"ר עפרה אקסלרוד מנהלת המכון לביקורת ותקנים של חומרי רפואה והאכיפה אוקטובר 2018 וס. מנהל מערך הרקוחות Keep in mind Know your product Know the regulatory

More information

Notes from Round Table 5. January 26 and 27, 2016

Notes from Round Table 5. January 26 and 27, 2016 Notes from Round Table 5 January 26 and 27, 2016 Topic: Facilitator: Scribe: Potency Assays: Cell Based vs. Non Cell Based Formats Sally Seaver, Seaver Associates LLC Cheryl Blaise, Bristol-Myers Squibb

More information

FRDA CLINICAL TRIALS. Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center. Meeting

FRDA CLINICAL TRIALS. Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center. Meeting FRDA CLINICAL TRIALS Susan L. Perlman, M.D. Clinical Professor of Neurology UCLA Medical Center US STUDIES FUNDED BY FARA, MDA, NAF, AND NIH FOR FA 18 16 14 12 10 8 6 4 2 0 1997 1998 1999 2000 2001 2002

More information

Introduction to CMC Regulatory Affairs

Introduction to CMC Regulatory Affairs Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4

More information

PHARMACEUTICAL MANUFACTURING

PHARMACEUTICAL MANUFACTURING PHARMACEUTICAL MANUFACTURING WHAT IS PHARMACEUTICAL MANUFACTURING IT IS THE PROCESS OF INDUSTRIAL SCALE SYNTHESIS OF PHARMACEUTICAL DRUG BY PHARMACEUTICAL COMPANIES. THE PROCESS CAN BE BROKEN DOWN INTO

More information

DEVELOPING AN IN VITRO RELEASE TESTING (IVRT) METHOD FOR THE VALIDATION OF SEMI-SOLID TOPICAL FORMULATIONS

DEVELOPING AN IN VITRO RELEASE TESTING (IVRT) METHOD FOR THE VALIDATION OF SEMI-SOLID TOPICAL FORMULATIONS DEVELOPING AN IN VITRO RELEASE TESTING (IVRT) METHOD FOR THE VALIDATION OF SEMI-SOLID TOPICAL FORMULATIONS EXECUTIVE SUMMARY The effective measurement of drug release of an active pharmaceutical ingredient

More information

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Adis Journals and Newsletters The premier collection of drug-focused medical journals adis.com Adis Journals and Newsletters The premier collection of drug-focused medical journals An invaluable resource for all involved in medical research, practice or teaching, drug regulation or reimbursement,

More information

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT Pharmaceutical IP Policy Issues Economics - Business Model IP TPP Global Challenges

More information

fact sheet 3 Introduction to Biosimilars & Regulatory Requirements

fact sheet 3 Introduction to Biosimilars & Regulatory Requirements 3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation

More information

Integrating Biospecimen Collection into Clinical Research

Integrating Biospecimen Collection into Clinical Research Integrating Biospecimen Collection into Clinical Research Janet E Dancey, MD, FRCPC Ontario Institute for Cancer Research Program for High Impact Clinical Trials National Cancer Institute of Canada Clinical

More information

IDSA is pleased to offer the following comments on specific priority areas identified by FDA:

IDSA is pleased to offer the following comments on specific priority areas identified by FDA: October 31, 2018 Shashi Malhotra Office of Acquisitions & Grants Services (OAGS) Food and Drug Administration Telephone: 240-402-7592 Email: Shashi.Malhotra@fda.hhs.gov SUBJECT: NOT-FD-18-16: Development

More information

PharmaMar A Biopharmaceutical Company

PharmaMar A Biopharmaceutical Company From Marine Expeditions to New Drugs in Oncology 26 June, 2007 Contents PharmaMar A Biopharmaceutical Company BioDiversity: The Business Case The Current Research Environment Value Creation: The R&D Process

More information

Presentation Outline

Presentation Outline IND Application Process: For The New Clinical Investigator John M. Centanni Department of Medicine University of Wisconsin Presentation Outline Journey from basic to clinical research Introduction to FDA

More information

Yodit Belew, MD Senior Medical Officer Division of Antiviral Products OAP/OND/CDER/FDA 1

Yodit Belew, MD Senior Medical Officer Division of Antiviral Products OAP/OND/CDER/FDA 1 Clinical Trials and Research in Children FDA s Perspectives for the development of antiviral products for the treatment of HIV infection in children: Regulatory considerations Pediatric HIV Cure Meeting

More information

FIRST YEAR PHARM. D. Know about the theory and their application in pharmacy PDM107 Remedial Mathematics

FIRST YEAR PHARM. D. Know about the theory and their application in pharmacy PDM107 Remedial Mathematics PDL101 Human Anatomy and Physiology FIRST YEAR PHARM. D Students learn the basic concepts of human organ, location, function, parts with model PDP102 Pharmaceutics Students will be exposed to various dosage

More information

Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA

Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA Overview of exploratory INDs Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA July, 15 16, 2008 David Jacobson-Kram, Ph.D. DABT Office of New Drugs Center for Drug Evaluation

More information

Investigational New Drug Application

Investigational New Drug Application Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution

More information

Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014

Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept. San Francisco, CA Tue 8 th, Apr 2014 Celerion s Symposia Series: Bridging the Gap from Phase I to Proof-of-Concept San Francisco, CA Tue 8 th, Apr 2014 Mind the Gap: Elements of a Bridging Strategy J. Fred Pritchard, Ph.D. Vice President,

More information

The Right Molecules. Designed. Delivered.

The Right Molecules. Designed. Delivered. The Right Molecules. Designed. Delivered. 400+ Worldwide Clients 80+ Medicinal Chemistry Programs 20+ Preclinical Candidates Delivered Since 2008 10+ In IND Stage 5 Entered Phase I Clinical Trials 2 Entered

More information

Response Adjusted for Duration of Antibiotic Risk (RADAR) Scott Evans, Ph.D., M.S. Harvard University

Response Adjusted for Duration of Antibiotic Risk (RADAR) Scott Evans, Ph.D., M.S. Harvard University Response Adjusted for Duration of Antibiotic Risk (RADAR) Scott Evans, Ph.D., M.S. Harvard University CTTI Statistical Think Tank Expert Meeting November 19, 2014 Special Thank You Kunal Merchant Dan Rubin

More information

Pediatric Assessment in Drug Development and Regulatory Approval in Japan

Pediatric Assessment in Drug Development and Regulatory Approval in Japan Pediatric Assessment in Drug Development and Regulatory Approval in Japan Mayumi SHIKANO, Ph.D. Associate Director, Center for Product Evaluation Pharmaceuticals and Medical Devices Agency 2016/3/8 1 Disclaimer

More information

An Introduction to Clinical Research and Development

An Introduction to Clinical Research and Development Bay Clinical R&D Services An Introduction to Clinical Research and Development The Complex Process by which New Drugs are Tested in Humans Anastassios D. Retzios, Ph.D. Outline of Presentation What is

More information

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables

More information

Managing Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD

Managing Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD Managing Risk and Uncertainty Through the Drug Life cycle Recent FDA Initiatives Theresa Mullin, PhD Director Office of Strategic Programs US FDA Center for Drug Evaluation and Research October 14, 2014

More information

Expanded Access and the Individual Patient IND

Expanded Access and the Individual Patient IND Expanded Access and the Individual Patient IND Research Wednesdays April 26, 2017 Erika Segear Johnson, PhD, RAC Associate Director of Regulatory Affairs Office of Regulatory Affairs and Quality Office

More information

PART I PAST, PRESENT, AND FUTURE OF PEDIATRIC DRUG DEVELOPMENT COPYRIGHTED MATERIAL

PART I PAST, PRESENT, AND FUTURE OF PEDIATRIC DRUG DEVELOPMENT COPYRIGHTED MATERIAL PART I PAST, PRESENT, AND FUTURE OF PEDIATRIC DRUG DEVELOPMENT COPYRIGHTED MATERIAL CHAPTER 1 A New Model for Children ANDREW E. MULBERG, MD Internal Medicine Portfolio, Johnson and Johnson Pharmaceutical

More information

Agreed with W. Cornell Graduate Program and Tri-I

Agreed with W. Cornell Graduate Program and Tri-I Drug Development Course From Molecule to Prescription Weill Cornell Graduate School - Tri-Institutional Therapeutics Discovery Institute ABOUT THIS COURSE This course has been designed in collaboration

More information

Development of paediatric formulations - points to consider

Development of paediatric formulations - points to consider Development of paediatric formulations - points to consider Workshop on Paediatric Formulations II London, 8 November 2011 Presented by: Ann Marie Kaukonen Scientific Administrator, Paediatric Medicines,

More information

Workflow for PBPK Modeling to Support Pediatric Research and Development

Workflow for PBPK Modeling to Support Pediatric Research and Development Workflow for PBPK Modeling to Support Pediatric Research and Development Jeff Barrett, PhD Vice-President, Interdisciplinary Pharmacometrics Program Sanofi 1 Industrial Strength PBPK 2 Outline Industrial

More information

The Science of Drug Discovery: The Intersection of Clinical Trials and Drug Development. Rich Whitley March 2, 2017

The Science of Drug Discovery: The Intersection of Clinical Trials and Drug Development. Rich Whitley March 2, 2017 The Science of Drug Discovery: The Intersection of Clinical Trials and Drug Development Rich Whitley March 2, 2017 The Many Faces of Clinical Research n Natural History Study n The impact of congenital

More information

Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium

Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium Successful and Faster Drug Development through Data Mining Dirk Belmans, Ph.D. SAS Belgium The Life-Cycle of a Successful Pharmaceutical Product Sales Costs Patent Filing R&D time to launch is decreasing

More information

Key Activities. Ofer Reizes, Ph.D. Skills Development Director

Key Activities. Ofer Reizes, Ph.D. Skills Development Director Key Activities Ofer Reizes, Ph.D. Skills Development Director 1 Key Activities Core Question: What key activities required for your Value Propositions? Key Partners Key Activities Key Resources Value Proposition

More information

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT Dr Philippe CASSIER Centre Léon Bérard, Lyon Outline Cancer & Oncology Drug development in oncology Specificity of phase I trials in oncology Study design

More information

First in Human Clinical Trials of medicines

First in Human Clinical Trials of medicines First in Human Clinical Trials of medicines Martin O Kane Head, Clinical Trials Unit, MHRA Topics MHRA Clinical Trials Unit Clinical Trials Legislation Assessment of a clinical trial and FIH considerations

More information

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ

Regulatory Challenges of Global Drug Development in Oncology. Jurij Petrin, M.D. Princeton, NJ Regulatory Challenges of Global Drug Development in Oncology Jurij Petrin, M.D. Princeton, NJ Topics General global R&D issues Regulatory issues with global oncology drug development US FDA initiatives

More information

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015

Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015 Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route

More information

Nomenclature for Biological and Biotechnological Substances, including Biosimilars/Generic Biopharmaceuticals

Nomenclature for Biological and Biotechnological Substances, including Biosimilars/Generic Biopharmaceuticals Nomenclature for Biological and Biotechnological Substances, including Biosimilars/Generic Biopharmaceuticals Gordon Johnston, RPh., M.S. VP Regulatory Affairs Generic Pharmaceutical Association WHO Headquarters

More information

May 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250

May 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250 DRUG DEVELOPMENT COURSE - FROM MOLECULE TO PRESCRIPTION WEILL CORNELL GRADUATE SCHOOL - TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE THURSDAYS FROM 3:00PM - 5:00PM AT 1300 YORK AVE, NEW YORK, N.Y.

More information

3+3 Consensus Meeting Introducing Model Based Dose Escalation in a Pharmaceutical Environment. James Matcham Head, ECD Biometrics 3 rd December 2014

3+3 Consensus Meeting Introducing Model Based Dose Escalation in a Pharmaceutical Environment. James Matcham Head, ECD Biometrics 3 rd December 2014 3+3 Consensus Meeting Introducing Model Based Dose Escalation in a Pharmaceutical Environment James Matcham Head, ECD Biometrics 3 rd December 2014 Agenda Background Challenge Actions Outcome 2 JMatcham

More information

Center for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review.

Center for Drug Evaluation and Research. CDER Small Business and Industry Assistance. (CDER SBIA) and New Drug Review. Center for Drug Evaluation and Research Small Business and Industry Assistance (CDER SBIA) and New Drug Review LT Renu Lal, Pharm.D. CDER Small Business and Industry Assistance Division of Drug Information

More information

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS

EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40

More information

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39)

BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39) ZAMRA BTIF BIOEQUIVALENCE TRIAL INFORMATION FORM (Medicines and Allied Substances Act [No. 3] of 2013 Part V Section 39) The Guidelines on Bioequivalence Studies to be consulted in completing this form.

More information

! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General

! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General ! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the

More information

Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union

Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction

More information

Drug Development & the FDA Pharmacy 309 November 2005

Drug Development & the FDA Pharmacy 309 November 2005 Goals & Objectives Drug Development & the FDA Pharmacy 309 November 2005 Tom Hazlet, Pharm.D., Dr.P.H. H375S 206.616.2732 thazlet@u... Be able to describe major regulatory events in the drug & biologic,

More information

Functional Classification of Medicine

Functional Classification of Medicine Research on Humans Functional Classification of Medicine Medicine and medical intervention can take any of five forms: (1) Therapeutic (curative): seeks to cure a disease or ailment. (2) Palliative: seeks

More information

Investigator-Initiated Research

Investigator-Initiated Research Vol. 4, No. 6, June 2008 Can You Handle the Truth? Investigator-Initiated Research By Harvey M. Arbit Commercial vs. Non-Commercial Clinical Research Between 1986 and 2006, pharmaceutical and biotech companies

More information

Models for Computer-Aided Trial & Program Design

Models for Computer-Aided Trial & Program Design Models for Computer-Aided Trial & Program Design Terrence Blaschke, M.D. VP, Methodology and Science Pharsight Corporation & Professor of Medicine & Molecular Pharmacology Stanford University MODELS What

More information

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB

Regulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full

More information

Sponsor- vs. investigator-initiated clinical intervention research. Jan P Vandenbroucke Leiden University Medical Center

Sponsor- vs. investigator-initiated clinical intervention research. Jan P Vandenbroucke Leiden University Medical Center Sponsor- vs. investigator-initiated clinical intervention research Jan P Vandenbroucke Leiden University Medical Center Outline The problem with industry-sponsored research The problem with investigator-initiated

More information

Improving the quality of decision analysis in early stage drug development, by design

Improving the quality of decision analysis in early stage drug development, by design Improving the quality of decision analysis in early stage drug development, by design Itay Perlstein, PhD Clinical Pharmacology and Drug Development Consulting Clinical PK Services itay@clinpkservicescom

More information

Interim Analysis of Randomized Clinical Trials. David L DeMets, PhD

Interim Analysis of Randomized Clinical Trials. David L DeMets, PhD Interim Analysis of Randomized Clinical Trials David L DeMets, PhD Need for Data Monitoring Phase I Trials (dose) Monitoring usually at local level Phase II Trials (activity) Most monitoring at local level

More information

Master List of Professional Electives Course Title Description Credit Hours. Note: This class only meets for the last 7 class periods of the semester.

Master List of Professional Electives Course Title Description Credit Hours. Note: This class only meets for the last 7 class periods of the semester. Course Number PHTH7044 PHRX7064 PHRX704C PHRX706 PHTH8048 PHRX 904 PHRX 904 Master List of Professional Electives Course Title Description Credit Hours Advanced Cardiac Life Support Emphasis (P only) Advanced

More information

Learning about Clinical Trials

Learning about Clinical Trials Learning about Clinical Trials A Guide for Individuals and Their Loved Ones INTRODUCTION Clinical trials help researchers answer important medical questions, providing information that may help with the

More information

Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA

Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics. December 3-4, 2012 PERI Training Facility ~ Arlington, VA Pharmceutical Toxicology: Tentative Agenda Pharmaceutical Toxicology: Toxicology in the Nonclinical Development of Drugs and Biologics December 3-4, 2012 PERI Training Facility ~ Arlington, VA Monday,

More information

REIMAGINING DRUG DEVELOPMENT:

REIMAGINING DRUG DEVELOPMENT: Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY

More information

A Global Pharmaceutical Service Provider (GPSP)

A Global Pharmaceutical Service Provider (GPSP) A Global Pharmaceutical Service Provider (GPSP) UBS 20 th Annual Global Healthcare Service Conference New York, 8 th February 2010 Disclaimer The documentation referred to into this presentation relates

More information

Replacing Analytical Methods for Release and Stability Testing CBER Perspective

Replacing Analytical Methods for Release and Stability Testing CBER Perspective Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood

More information

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA

More information

19 th SEC- (Antimicrobial, antiparasitic& antifungal, antiviral) meeting held on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi

19 th SEC- (Antimicrobial, antiparasitic& antifungal, antiviral) meeting held on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 19 th SEC- (Antimicrobial, antiparasitic& antifungal, antiviral) meeting held on 22-06- 2015 at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 110 002 Recommendation:- The 19th SEC (Antimicrobial, antiparasitic&

More information

EXPERT COLLECTION. Explore our leading medical review series

EXPERT COLLECTION. Explore our leading medical review series EXPERT COLLECTION Explore our leading medical review series Introducing the EXPERT COLLECTION The Taylor & Francis Expert Collection is the world s largest series of review journals in research, development,

More information

Pre-consultation system at the authority for clinical trials and NDA in Japan

Pre-consultation system at the authority for clinical trials and NDA in Japan Pharmaceuticals and Medical Devices Agency Pre-consultation system at the authority for clinical trials and NDA in Japan Takeyuki SATO Associate Director, Centre for Product Evaluation Pharmaceuticals

More information

Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim

Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim S Blech EBF Focus Workshop: Metabolite Profiling and Quantification Strategies in Drug R&D Sep 25,

More information

Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität

Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität PD Dr. Elke Röhrdanz Präklinik Fachgebiet Klinische Prüfung

More information

INTRODUCTION TO DRUG DISCOVERY

INTRODUCTION TO DRUG DISCOVERY INTRODUCTION TO DRUG DISCOVERY AND ITS FUNDING including the Alabama Drug Discovery Alliance Maaike Everts, PhD Associate Director Topics to Cover The Drug Discovery and Development Pipeline Funding Opportunities

More information

THE COMMON TECHNICAL DOCUMENT: TAKING INDIAN NDA PROCESS TOWARDS GLOBALIZATION

THE COMMON TECHNICAL DOCUMENT: TAKING INDIAN NDA PROCESS TOWARDS GLOBALIZATION Review Article Bhalodiya H. A.*, Boda J. M., Shah J. S., Patel P. B., Vaghela J. P. Department of Quality Assurance, S. J. Thakkar Pharmacy College, Rajkot-360005, Gujarat, India. *Corresponding author

More information

NIAID Resources to Facilitate Medical Countermeasure Development

NIAID Resources to Facilitate Medical Countermeasure Development NIAID Resources to Facilitate Medical Countermeasure Development Paula Bryant, Ph.D. Senior Scientific Officer Concept Acceleration Program Biodefense, Research Resources, and Translational Research (OBRRTR)

More information